+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?



Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?



Virchows Archiv 464(3): 367-378



Gastric cancer is an aggressive disease often diagnosed at an advanced stage. Despite improvements in surgical and adjuvant treatment approaches, gastric cancer remains a global public health problem with a 5-year overall survival of less than 25 %. This is a heterogeneous disease, both in terms of biology and genetics, and many prognostic biomarkers have been pointed out in the literature; nevertheless, their application remains debatable. In this review, we opted to give relevance to those biomarkers that have been the subject of studies with significant statistical power, which have been replicated and have been/are in targeted therapy clinical trials and, which as a consequence, have their prognostic and/or predictive value established. Some gastric cancer biomarkers that may help in defining the course of treatment are also discussed. Accepted practical guidelines, wet-lab protocols for the detection of these biomarkers, as well as ongoing and completed clinical trials have been compiled. In summary, clinical approaches based on the combination of correct staging with targeted and conventional systemic therapies may improve gastric cancer patients' outcome, but are only in their infancy. Some major challenges in identifying reliable prognostic/predictive biomarkers are individual genetic variation and tumour heterogeneity that often influence response to therapy and drug resistance. Prognostic and predictive biomarkers may nevertheless be extremely valuable to correctly stratify gastric cancer patients for treatment and, ultimately, improve survival.

(PDF emailed within 0-6 h: $19.90)

Accession: 051813402

Download citation: RISBibTeXText

PMID: 24487788

DOI: 10.1007/s00428-013-1533-y


Related references

MicroRNAs May Serve as Emerging Molecular Biomarkers for Diagnosis and Prognostic Assessment or as Targets for Therapy in Gastric Cancer. Asian Pacific Journal of Cancer Prevention 16(12): 4813-4820, 2016

Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. World Journal of Gastroenterology 20(14): 3858-3874, 2015

CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer. World Journal of Gastroenterology 24(42): 4738-4749, 2019

Synergistic role between p53 and JWA: prognostic and predictive biomarkers in gastric cancer. Plos One 7(12): E52348-E52348, 2013

Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours. Cancer Treatment Reviews 70: 209-222, 2018

Prognostic and putative predictive biomarkers of gastric cancer for personalized medicine. Diagnostic Molecular Pathology 22(3): 127-137, 2014

How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer. Oncologist 19(10): 1046-1055, 2015

Prognostic Value of Inflammatory Biomarkers in Gastric Cancer Patients and the Construction of a Predictive Model. Digestive Surgery: 1-10, 2018

Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer. Biomed Research International 2017: 7869802-7869802, 2017

Prognostic value of pre-operative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model. Journal of Translational Medicine 13: 66-66, 2016

Prognostic and predictive blood biomarkers in gastric cancer and the potential application of circulating tumor cells. World Journal of Gastroenterology 24(21): 2236-2246, 2018

Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. Clinical Colorectal Cancer 9(5): 274-281, 2011

Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. World Journal of Gastroenterology 22(30): 6944-6954, 2016

HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology 140(8): 1441-1449, 2014

MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?. Oncotarget 6(27): 23323-23341, 2016